Answers are grounded in this paper and cite their sources.
Study discovers a nonacidic small-molecule inhibitor of NaCT, suggesting therapeutic potential in metabolism disorders.
= 25 nM), shows exceptional selectivity (>1000-fold over other SLC13 transporters), and has robust cellular activity, whereas BI01372674 shows no measurable activity. Together, these compounds provide valuable tools for probing the physiological and pathological roles of NaCT in metabolism and disease.
No takes yet. Share an insight, caveat, or question.
Quigley et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: